Following a recent patent lawsuit, SK Bioscience emerges victorious over Pfizer in the realm of pneumococcal vaccines. Looking ahead, SK Bioscience is poised to strengthen its position in the global market. In 2027, the company will introduce SKYPneumo for domestic manufacturing and sales. Moreover, a collaboration with Sanofi has led to the development of a 21-valent pneumococcal conjugate vaccine, currently in Phase 3 global clinical trials since late 2024. The partnership is also focusing on an advanced pneumococcal vaccine anticipated to provide enhanced protection compared to existing alternatives.
Read more from medicaldialogues.in
